STOCK TITAN

[SCHEDULE 13D/A] Staar Surgical Co SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Broadwood Partners, L.P., Broadwood Capital, Inc. and Neal C. Bradsher (collectively the “Reporting Persons”) filed Amendment No. 35 to Schedule 13D on STAAR Surgical Company (NASDAQ: STAA). The group now reports beneficial ownership of 13,545,391 common shares (13,519,491 held jointly plus 25,900 held solely by Bradsher), representing 27.3 % of the 49,553,035 shares outstanding. Voting and dispositive power is shared over virtually all shares, underscoring the bloc’s ability to influence corporate actions.

On 5 Aug 2025 STAAR announced a definitive agreement to be acquired by Alcon. The Reporting Persons have not decided how they will vote on the transaction and are demanding books & records under Delaware §220 to evaluate the sale process. They are also exploring strategic alternatives, including contacting other potential bidders, and reserve the right to alter their holdings or take additional actions. No share transactions were executed in the past 60 days, and no borrowings were used to finance the stake.

Positive

  • None.

Negative

  • None.

Insights

TL;DR – 27.3 % holder questions Alcon deal; vote still undecided, raising execution risk.

Broadwood’s sizable stake gives it practical veto power over the Alcon merger, especially if the agreement requires a majority-of-outstanding vote. The §220 demand suggests concerns about process fairness and value maximization. While no explicit opposition is declared, the filing signals willingness to solicit alternative bids, which can prolong timelines or extract a higher price. Absence of recent trading indicates commitment to retaining influence. Overall impact: heightened deal uncertainty rather than immediate collapse.

TL;DR – Governance activism underway; Broadwood seeks diligence on board’s sale process.

The filing highlights active monitoring of fiduciary obligations. By requesting records, Broadwood pressures the board to demonstrate a robust auction and could strengthen any future appraisal or litigation stance. Investors should watch for subsequent filings—opposition from a 27 % holder can materially sway ISS/Glass Lewis recommendations and voting outcomes. Potential for a superior proposal exists but is speculative; immediate takeaway is elevated governance scrutiny and possible legal friction.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Broadwood Partners, L.P.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher/President of Broadwood Capital, Inc.
Date:08/08/2025
Broadwood Capital, Inc.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher/President
Date:08/08/2025
Neal C. Bradsher
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher
Date:08/08/2025
Comments accompanying signature:
* This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

FAQ

How much of STAAR Surgical (STAA) does Broadwood currently own?

The group reports 13,545,391 shares, or 27.3 % of outstanding common stock.

What event triggered this Schedule 13D/A amendment?

STAAR’s 5 Aug 2025 agreement to be acquired by Alcon prompted the updated filing on 7 Aug 2025.

Is Broadwood supporting the Alcon acquisition of STAA?

No decision has been made; Broadwood is evaluating the deal and considering alternatives.

What actions is Broadwood taking to assess the merger?

Broadwood has made a Delaware §220 demand for books and records to review the sale process.

Were any STAA shares bought or sold in the 60 days before the filing?

No. The Reporting Persons report no transactions during that period.

How is the 13D stake financed?

Purchases were funded from working capital and Bradsher’s personal funds; no specific borrowings were used.